David G. Sawutz

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial

Stephen A. Boorjian, Mehrdad Alemozaffar, Badrinath R. Konety et al. · The Lancet Oncology · 2020 · 412 citations · Full text

Urology, Oncology, Genitourinary Cancer +2

Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized Study

Neal D. Shore, Stephen A. Boorjian, Daniel Canter et al. · Journal of Clinical Oncology · 2017 · 167 citations · Full text

Design of potent non-peptide competitive antagonists of the human bradykinin B2 receptor

Joseph M. Salvino, Peter R. Seoane, Brent Douty et al. · Journal of Medicinal Chemistry · 1993 · 96 citations · Full text

Peptide Engineering, Immunology, Altmetric Attention Score +21

The nonpeptide WIN 64338 is a bradykinin B2 receptor antagonist.

David G. Sawutz, Joseph M. Salvino, Roland E. Dolle et al. · Proceedings of the National Academy of Sciences · 1994 · 89 citations · Full text

Immunology, Peptide Science, Pharmacotherapy +19

Effects of peptide and nonpeptide antagonists of bradykinin B2 receptors on the venoconstrictor action of bradykinin.

François Marceau, Luc Lévesque, G. Drapeau et al. · Journal of Pharmacology and Experimental Therapeutics · 1994 · 71 citations